TRAPIDIL

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H15N5
Molecular Weight	205.2596
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN(CC)C1=CC(C)=NC2=NC=NN12

InChI

InChIKey=GSNOZLZNQMLSKJ-UHFFFAOYSA-N

InChI=1S/C10H15N5/c1-4-14(5-2)9-6-8(3)13-10-11-7-12-15(9)10/h6-7H,4-5H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C10H15N5
Molecular Weight	205.2596
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB09283
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/19110816

Trapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney disease. Used to treat patients with ischemic coronary heart, liver, and kidney disease.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Thrombin-induced Thromboxane formation 1 Target ID: Thrombin-induced Thromboxane formation Sources: http://www.ncbi.nlm.nih.gov/pubmed/3248101	Inhibitor 8504	410.0 µM [IC50]
Platelet-derived growth factor receptor beta 56 Target ID: CHEMBL1913 Sources: http://www.ncbi.nlm.nih.gov/pubmed/7861694	Antagonist 2849
C-C motif chemokine 2 2 Target ID: P28292 Gene ID: 1.00009128E8 Gene Symbol: CCL2 Target Organism: Oryctolagus cuniculus (Rabbit) Sources: http://www.ncbi.nlm.nih.gov/pubmed/10576207	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Coronary heart disease 43 Sources: http://memim.com/trapidil.html	Primary		Approved 8583	Trapidil Approved Use Trapidil is primarily used for the treatment of coronary heart disease (CHD ) by reducing the preload and afterload of the heart muscle, especially in patients with an intolerance to the standard used ingredients from the class of nitrates. In addition, it decreases after a myocardial infarction, the incidence of other cardiovascular complications. In patients with peripheral arterial occlusive disease Trapidil improves blood flow to the limbs and walking performance. Launch Date 2000

C_max

Value	Dose	Analyte	Population
5.14 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8904615/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	TRAPIDIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.01 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8904615/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TRAPIDIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8904615/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	DESETHYLTRAPIDIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8904615/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DESETHYLTRAPIDIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.74 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8904615/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DESETHYLTRAPIDIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.67 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8904615/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TRAPIDIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
20.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8904615/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	TRAPIDIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
13.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8904615/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TRAPIDIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
16.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8904615/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	DESETHYLTRAPIDIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
16.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8904615/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DESETHYLTRAPIDIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
34.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8904615/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DESETHYLTRAPIDIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
20.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8904615/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TRAPIDIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
1.31 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8904615/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	TRAPIDIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.14 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8904615/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TRAPIDIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.41 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8904615/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TRAPIDIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
200 mg 3 times / day multiple, oral Studied dose Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8904615/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8904615/	Other AEs: Weakness... Other AEs: Weakness (1 pt) Sources: https://pubmed.ncbi.nlm.nih.gov/8904615/

AEs

AE	Significance	Dose	Population
Weakness	1 pt	200 mg 3 times / day multiple, oral Studied dose Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8904615/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8904615/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 activator 150	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP19A1 429 UMAT 30 CYP2C19 2057 BSEP 550 BCRP 910 P-gp 1741

Drug as perpetrator

Target	Modality	Activity
BCRP 985	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1325#sid=14745540	no
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/743139#sid=144204129	no
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/778#sid=14745540	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/777#sid=14745540	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/891#sid=11112623	no
CYP3A4 2633	activator 342 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/885#sid=11112623	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/884#sid=11112623	no
P-gp 1932	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/799#sid=14745540	no
UMAT 30	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/588550#sid=14745540	no
BSEP 554	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/22961681/	unlikely [IC50 627.8 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671199#sid=170465770	yes [IC50 12.8647 uM]

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/588834#sid=144204129

PubMed

Title	Date	PubMed
Osteitis fibrosa is mediated by Platelet-Derived Growth Factor-A via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chronic hyperparathyroidism.	2008-11	18635661

Patents

Sample Use Guides

In Vivo Use Guide

Adults: Oral: 400-600 mg/day in divided doses

Route of Administration: Oral

In Vitro Use Guide

The addition of 100 to 400 ug/ml Trapidil significantly reduced cell proliferation induced by different growth factors (FCS, PDGF-BB, bFGF, EGF)

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:09:36 GMT 2025` Edited by `admin` on `Mon Mar 31 18:09:36 GMT 2025`
Record UNII	EYG5Y6355E
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ROCORNAL

Preferred Name

English

TRAPIDIL

Official Name

English

TRAPIDIL [MI]

Common Name

English

Trapidil [WHO-DD]

Common Name

English

AR 12008

Code

English

TRAPIDIL [JAN]

Common Name

English

TRAPIDIL [MART.]

Common Name

English

trapidil [INN]

Common Name

English

AR-12008

Code

English

TRAPIDIL [EP MONOGRAPH]

Common Name

English

7-(DIETHYLAMINO)-5-METHYL-S-TRIAZOLO(1,5-A)PYRIMIDINE.

Systematic Name

English

Classification Tree Code System Code

WHO-VATC

QC01DX11